Navigation Links
Echo Therapeutics Announces Proposed Public Offering
Date:11/27/2012

PHILADELPHIA, Nov. 27, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced that it intends to offer for sale its common stock in an underwritten public offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

Aegis Capital Corp. is acting as the sole book-running manager for the offering.

The offering is being made pursuant to a shelf registration statement that Echo previously filed with the Securities and Exchange Commission (the "SEC") and which is effective.  A preliminary prospectus supplement and accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov.  Electronic copies of the preliminary prospectus supplement, when available, and accompanying base prospectus may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system.  Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.  Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements, including statements regarding Echo's proposed public offering.  These statements are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to general market conditions and the other risks and uncertainties identified and described in more detail in Echo's filings with the Securities and Exchange Commission.   Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio                                         
Director, Investor Relations and Corporate Communications
(215) 717-4104 
colimpio@echotx.com                                       

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2017)... ivWatch, LLC, the leading provider of continuous monitoring devices ... been awarded an Innovative Technology contract from Vizient, Inc., the largest ... ... the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch ...
(Date:8/28/2017)... Aug. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... Monday, September 11, 2017, in New York ... officer, is scheduled to present at 11:05 a.m. Eastern Time. ... at http://ir.hill-rom.com/events.cfm . A recorded replay will be available ... December 10, 2017. ...
(Date:8/25/2017)... Aug. 25, 2017  Innovation Zed ( www.innovationzed.com ), an Irish medtech ... South Yorkshire and Bassetlaw, England ... used with diabetes patients as part of a national NHS Test Bed ... Innovation ... InsulCheck Connect, a snap-on accessory for disposable insulin ...
Breaking Medicine Technology:
(Date:9/19/2017)... Lewisville, TX (PRWEB) , ... September 19, 2017 , ... ... in the United States, named Dr. Howard Ng, as the new Medical Director of ... will be the new facility Medical Director of our Pflugerville- FM 685 location,” said ...
(Date:9/19/2017)... ... 2017 , ... When it comes to household safety, there are few priorities ... to keep babies and toddlers safe, and there's no better time for companies to ... to Check Labels, Brands that sell all kinds of common consumer products should spend ...
(Date:9/19/2017)... ... September 19, 2017 , ... With Netmail ... contractors in the United States, can easily manage all of their data, apply ... on premise platforms simultaneously. “As a construction company,” says Ryan Sinnwell, the Infrastructure ...
(Date:9/18/2017)... ... , ... A September 7 article on BBC News describes new ... world’s most common and least expensive medications, may be able to stimulate stem cells ... California Dental Group and Calabasas Dental Care says that, while it’s likely to be ...
(Date:9/18/2017)... ... September 18, 2017 , ... Allegheny Health Network’s (AHN) string of ... the fifth consecutive year, AHN earned more honors than any health care provider in ... a dinner Sept. 14 at the Omni William Penn Hotel in downtown Pittsburgh included:, ...
Breaking Medicine News(10 mins):